

## Enteral Feeding In-Line Cartridge (EFICTM)

<b>Policy ID:</b>	HHO-DE-MP-1010
<b>Approved By:</b>	Highmark Health Options – Market Leadership
<b>Provider Notice Date:</b>	
<b>Original Effective Date:</b>	09/20/2021
<b>Annual Approval Date:</b>	01/24/2022
<b>Last Revision Date:</b>	01/24/2022
<b>Products:</b>	Medicaid
<b>Application:</b>	All participating hospitals and providers
<b>Page Number(s):</b>	1 of 4

### Disclaimer

Highmark Health Options medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

### POLICY STATEMENT

Highmark Health Options may provide coverage under medical surgical benefits of the Company's Medicaid products for medically necessary enteral feeding in-line cartridge.

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person's unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

The qualifications of the policy will meet the standards of the National Committee for Quality Assurance (NCQA) and the Delaware Department of Health and Social Services (DHSS) and all applicable state and federal regulations.

### DEFINITIONS

**Highmark Health Options (HHO)** – Managed care organization serving vulnerable populations that have complex needs and qualify for Medicaid. Highmark Health Options members include individuals and families with low income, expecting mothers, children, and people with disabilities. Members pay nothing to very little for their health coverage. Highmark Health Options currently services Delaware Medicaid: Delaware Healthy Children Program (DHCP) and Diamond State Health Plan Plus members.

**Enteral Feeding (EN)** – Refers to intake of food via the gastrointestinal (GI) tract. Enteral feeding may mean nutrition taken through the mouth or through a tube that goes directly to the stomach or small intestine.

**Fat Malabsorption** – Inadequate assimilation of dietary substances due to defects in digestion, absorption, or transport.

**Lipase** – A digestive enzyme that breaks down fats (triglycerides) into absorbable fatty acids and monoglycerides.

**RELIZORB™ (Alcresta Therapeutics)** – A single-use, point-of-care digestive enzyme cartridge device that contains an enzyme called lipase. Relizorb increases the delivery of absorbable calories from an enteral tube feeding formula by connecting the cartridge in-line with an enteral pump feed set and pump extension set. The Relizorb device is connected to the enteral tube feeding pump. The device is only for enteral feeding uses and is only intended for the connection to enteral feeding lines.

**De Novo FDA Classification** – The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the de novo classification option, which is also known as Evaluation of Automatic Class III Designation. This option provides an alternate pathway to classify novel devices of low-to-moderate risk. Devices that are classified through the de novo process may be marketed and used for future 510(k) submissions.

## PROCEDURES

1. A prior authorization is required if billed charges are greater than \$500.00.
2. Medical Necessity Guidelines

The use of Enteral Feeding In-Line Cartridge (EFIC) (e.g., Relizorb) with tube enteral feedings was approved by the Food and Drug Administration in July 2017, is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

3. Post-payment Audit Statement

The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by Highmark Health Options at any time pursuant to the terms of your provider agreement.

4. Place of Service: Outpatient

## GOVERNING BODIES APPROVAL

On July 20, 2017, Alcresta Therapeutics, Inc. received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Relizorb to be used in pediatric patients suffering from fat malabsorption.

On November 20, 2015, Alcresta Therapeutics, Inc. received de novo approval from the FDA to market Relizorb and to use Relizorb in adult patients. Relizorb is the first digestive enzyme cartridge that was created and designed to mimic the normal pancreatic function by breaking down fats in the enteral tube feeding formula.

## CODING REQUIREMENTS

CPT code	Description
B4105	In-line cartridge containing digestive enzyme(s) for enteral feeding, each.

## REIMBURSEMENT

Participating facilities will be reimbursed per their Highmark Health Options contract.

## SUMMARY OF LITERATURE

Fat malabsorption is a common condition in patients who cannot produce adequate digestive enzymes due to compromised pancreatic function. The condition causes a patient's gastrointestinal (GI) system to function incorrectly (NIH, 2017). Many diseases can cause malabsorption such as cystic fibrosis (CF), trauma to the pancreas, surgery to remove part of the pancreas, pancreatitis, and pancreatic cancer (BioSpace, 2016). Fat malabsorption affects many aspects of improving the health of critically ill patients, including a patient's ability to maintain or gain weight, immune system, wound healing, muscle strength, and psychological factors (Stroud, 2003). Patients with conditions that compromise pancreatic function do not produce enough pancreatic lipase necessary for fat hydrolysis (BioSpace, 2016). Individuals who have these conditions and receive enteral tube feeding may be receiving an incomplete breakdown of fats which can lead to decreased calorie intake, reduced fat digestion (e.g., omega-3 fatty acids), deficiencies of fat-soluble vitamins, and increased GI symptoms (Alcresta Therapeutics, 2017).

Due to the problems posed by fat malabsorption, there is clinical management in place which consists of enteral tube feeding. The enteral tube feeding consists of supplemental nutritional liquids that are delivered to the gastrointestinal tract through a feeding tube into the stomach or small intestine (Stroud, 2003). An enteral feeding in-line cartridge (EFIC) was designed to mimic the normal pancreatic function by breaking down fats in the enteral tube feeding formula. Breaking down the fats prior to ingestion will allow the patient who suffers from fat malabsorption to absorb more calories from omega-3 fatty acids, monoglycerides, and fat-soluble vitamins (Maki, 1993).

In 2017, the FDA approved the pediatric use (ages 5 years and above) of Relizorb after a study conducted by Alcresta Therapeutics. In conclusion, despite long-term use of EN in conjunction with PERT products, patients with CF exhibit low baseline levels of omega-3 FAs DHA and EPA, as well as BMI or BMI percentiles that are below target. This study demonstrated that digestive cartridge use was safe, well tolerated, and resulted in an almost 3-fold increase in absorption of omega-3 FAs DHA and EPA, a marker of fat absorption, in adults and children with CF and EPI requiring EN. Furthermore, a decrease in the occurrence and severity of reported GI symptoms and an increase in reported preservation of appetite and ability to consume breakfast was observed with digestive cartridge use.

## References

Alcresta Therapeutics. Relizorb: (Immobilized Lipase) Cartridge, 2017. Accessed on April 5, 2017.

Alcresta Therapeutics. Alcresta Therapeutics receives 510(K) Clearance for use of Relizorb in Children, July 20, 2017. Accessed on April 27, 2018.

Alcresta Therapeutics. Alcresta Therapeutics receives New Innovative Technology Contract from Vizient, Inc. For Relizorb (Immobilized LIPASE) Cartridge, September 1, 2017. Accessed on April 27, 2018.

BioSpace, October 28, 2016. PRNewswire: Alcresta' Relizorb Increases Fat Absorption in Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition. Newton, Massachusetts. Accessed on April 14, 2017.

Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Medical Nutrition Therapy (180.1), October 1, 2002.

ClinicalTrials.gov. Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb), ClinicalTrials.gov Identifier: NCT02598128. Last updated: June 2016. Accessed on April 7, 2017.

Federal Register: Food and Drug Administration (FDA). Medical Devices; Gastroenterology – Urology Devices; Classification of the Enzyme Packed Cartridge, October 16, 2017. Accessed on April 27, 2018.

Freedman, Steven; Orenstein, David; Black, Philip; Brown, Perry; McCoy, Karen; Stevens, John; Grujic, Danica; Clayton, Russell. Increased Fat Absorption From Enteral Formula Through an In-line Digestive Cartridge in Patients With Cystic Fibrosis, *Journal of Pediatric Gastroenterology and Nutrition*: July 2017 - Volume 65 - Issue 1 - p 97-101 doi: 10.1097/MPG.0000000000001617

Hayes, Inc. Relizorb (Alcresta Pharmaceuticals), February 4, 2016. Accessed on April 14, 2017.

Hayes, Inc. Relizorb (Alcresta Pharmaceuticals. Search & Summary, October 15, 2018. Accessed on March 18, 2019.

Maki, J., Neelagiri, M., Olshaw, B., Devarakonda, S., Loring, G. ePS05.2 Novel point of care immobilized lipase device (EFIC™) is compatible with a range of nutritional formulas and can simplify delivery of hydrolyzed fat during tube feeding, 1993. *Journal of Cystic Fibrosis*. Accessed on April 10, 2017.

National Institutes of Health (NIH): U.S. National Library of Medicine, 2017. MedlinePlus: Malabsorption. Bethesda, Maryland. Accessed on April 14, 2017.

Stroud, M., Duncan, H., Nightingale, J. Guidelines for enteral feeding in adult hospital patients: Institute of Human Nutrition, 2003. Accessed on April 7, 2017.

**POLICY UPDATE HISTORY**

09/20/2021	Approved in Medical Policy Committee
01/24/2022	Annual review